We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Published Online:https://doi.org/10.2217/fon-2020-0265
Free first page

References

  • 1. Guy GP Jr, Thomas CC, Thompson T et al. Vital signs: melanoma incidence and mortality trends and projections – United States, 1982–2030. MMWR Morb. Mortal. Wkly Rep. 64(21), 591–596 (2015).
  • 2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C et al. Global, regional and national cancer incidence, mortality, years of life lost, years lived with disability and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 4(11), 1553–1568 (2018).
  • 3. Paulson KG, Gupta D, Smith TS, Veatch JR et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol. 154(1), 57–64 (2020).
  • 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
  • 5. Neal RD, Tharmanathan P, France B et al. Is increased time to diagnosis and treatment of symptomatic cancer associated with poorer outcomes? Systematic review. Br. J. Cancer 112(Suppl.1), S92–S107 (2015).
  • 6. Keeble S, Abel GA, Saunders CL et al. Variation in promptness of presentation among 10,297 patients subsequently diagnosed with one of 18 cancers: evidence from a National Audit of Cancer Diagnosis in primary care. Int. J. Cancer 135(5), 1220–1228 (2014).
  • 7. Kasparian N, McLoone JK, Meiser B. Skin cancer-related prevention and screening behaviors: a review of the literature. J. Behav. Med. 32, 406–428 (2009).
  • 8. Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J. Am. Acad. Dermatol. 75(5), 967–974 (2016).
  • 9. Baade PD, English DR, Youl PH, McPherson M, Elwood JM, Aitken JF. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch. Dermatol. 142, 1422–1427 (2006).
  • 10. Henley J, Anderson RN, Thomas CC, Massetti G, Peaker B, Richardson LC. Invasive cancer incidence, 2004–2013 and deaths, 2006–2015, in nonmetropolitan and metropolitan counties-United States. MMWR Morb. Mortal. Wkly. Rep. 66(14), 1–12 (2017).
  • 11. Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P. Challenges of rural cancer care in the United States. Oncology 29(9), 633–640 (2015).
  • 12. Agency for Healthcare Research and Quality. Screening for skin cancer in adults: an updated systematic evidence review for the U.S. Preventive Services Task Force (2015). www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review159/skin-cancer-screening2
  • 13. Johnson M, Leachman S, Aspinwall L et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 4(1), 13–37 (2017).
  • 14. Torres A. AAD statement on USPSTF recommendation on skin cancer screening. The American Academy of Dermatology (2016). www.aad.org/media/newsreleases/aad-statement-on-uspstf
  • 15. Jones MS, Torisu-Itakura H, Flaherty DC et al. Second primary melanoma: risk factors, histopathologic features, survival, and implications for follow-Up. Am. Surg. 82, 1009–1013 (2016).
  • 16. Paddock LE, Lu SE, Bandera EV, Rhoads GG et al. Skin self-examination and long-term melanoma survival. Melanoma Res. 26, 401–408 (2016).
  • 17. Robinson JK, Wayne JD, Martini MC, Hultgren BA, Mallett KA, Turrisi R. Early detection of new melanomas by patients with melanoma and their partners using a structured skin self-examination skills training intervention: a randomized clinical trial. JAMA Dermatol. 152(9), 979–985 (2016).
  • 18. Stapleton JL, Turrisi R, Mallett KA, Robinson JK. Correspondence between pigmented lesions identified by melanoma patients trained to perform partner-assisted skin self-examination and dermatological examination. Cancer Epi. Biomarkers and Prevention. 24, 1247–1253 (2015).
  • 19. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in surveillance, epidemiology, and end results (SEER) program. Arch. Dermatol. 144(4), 515–521 (2008).
  • 20. Wong AYS, Froslev T, Dearing L et al. The association between partner bereavement and melanoma: cohort studies in the UK and Denmark. Br. J. Dermatol. doi.org/10.1111/bjd.18889 (2020) [Epub ahead of print].